The identification of this pathway as a mediator of immune suppression within PD tumors has important potential therapeutic implications, as IDO1 is upregulated in many cancers (Cheong and Sun, 2018; Hornyák et al., 2018; Liu et al., 2018). Here, IDO1 is linked to cancer.